Ann: FY22 Q1 - Activity Report and Appendix 4C Cashflow Statement, page-73

You may not have heard, students are already approved to start coming back via pilot programs in Dec, see here: https://www.study.sydney/return
Originally the TGA hadn't approved Sinovac, but then earlier this month it was added to the TGA schedule too, you can see that here: https://www.tga.gov.au/media-release/tga-advice-recognition-covid-19-vaccines-not-registered-australia-used-internationally
Next quarter end report will be very interesting to see the affect on revenue. After that we can start making projections for full year revenue as we will have a clearer picture. Still anyone's guess, my thinking is somewhere between 90-120m. Apply around a 5x P/S based on growth rates and away you go.